- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02207257
Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, single-blind, sequential group, ascending PER977 reversal dose study in healthy volunteers. Subjects will be randomized in a 4:1 ratio to receive either PER977 or placebo. All subjects will receive a single dose of edoxaban 60 mg on Days 1-4. On Days 3 and 4, study drug will be administered 3 hours following edoxaban. Beginning with Cohort 2, study drug will be administered only to those subjects with a minimum increase in whole blood clotting time >25% above baseline.
Pharmacokinetic assessment of PER977 and tis metabolite, and edoxaban and its metabolite will be performed. Pharmacodynamic assessment of WBCT and Point of Care prothrombin time will be performed. Safety will be assessed throughout the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Quintiles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults age 18 to 65 years, inclusive
- Laboratory values are not clinically significant
- No clinically significant findings on 12-lead electrocardiogram
- Body mass index (BMI) 18 to ≤ 32 kg/m2, inclusive
- Male subjects agree to use appropriate contraception .
- Female subjects may be post-menopausal or, if of child-bearing potential, must have a negative serum pregnancy test prior to enrollment, and must agree to use two forms of acceptable contraception for the duration of the study and for a minimum of one complete menstrual cycle or 28 days following discharge from the study.
- Subjects must sign informed consent
Exclusion Criteria:
- History or current evidence of clinically significant disease, liver function tests greater than the upper limit of normal (presence of Gilbert's syndrome is acceptable), QTcF > normal (440±10 msec for males or 460±10 msec for females).
- History of unexplained syncope
- History of major bleeding, trauma, surgical procedure of any type, or vaginal delivery within six months prior to screening
- History of peptic ulcer, gastrointestinal bleeding, including the mouth, within six months prior to screening
- History of minor bleeding episodes such as epistaxis, rectal or hemorrhoidal bleeding or gingival bleeding within 1 month prior to screening
- Personal or family history of clotting disorder or abnormality, excessive bleeding, thrombovascular disease or any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, or history of heparin-induced thrombocytopenia
- Females with a history of dysfunctional uterine bleeding, menorrhagia , metrorrhagia or polymenorrhea
- Pregnant or breast-feeding
- Males with a history of hormone therapy within 3 months prior to screening
- Administration of any blood product or anticoagulant within 3 months prior to study entry or any non steroidal anti-inflammatory drug or cyclooxygenase inhibitor within 2 weeks prior to screening
- Taking any type of chronic medication within the 4 weeks prior to study entry (use of hormonal contraceptives is acceptable)
- Positive serologic test for HIV, HCV-Ab, or HBsAG
- Donation of blood or blood products within 56 days prior to screening
- Smokers or use of tobacco and/or nicotine containing products within 3 months prior to dosing as determined by the subject's verbal history
- Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
- History of participation in any prior study of PER977 or edoxaban
- Active drug or alcohol dependence within the prior 12 months or any condition that, in the opinion of the Investigator, would interfere with adherence to study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Subjects will receive 60 mg edoxaban in the morning on Days 1-2.
On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
|
Reversal of edoxaban-induced anticoagulation
Reversal of edoxaban-induced anticoagulation
|
Experimental: Cohort 2
Subjects will receive 60 mg edoxaban in the morning on Days 1-2.
On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
|
Reversal of edoxaban-induced anticoagulation
Reversal of edoxaban-induced anticoagulation
|
Experimental: Cohort 3
Subjects will receive 60 mg edoxaban in the morning on Days 1-2.
On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
|
Reversal of edoxaban-induced anticoagulation
Reversal of edoxaban-induced anticoagulation
|
Experimental: Cohort 4
Subjects will receive 60 mg edoxaban in the morning on Days 1-2.
On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10).
Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
|
Reversal of edoxaban-induced anticoagulation
Reversal of edoxaban-induced anticoagulation
|
Experimental: Cohort 5
Subjects will receive 60 mg edoxaban in the morning on Days 1-2.
On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10).
A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
|
Reversal of edoxaban-induced anticoagulation
Reversal of edoxaban-induced anticoagulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whole blood clotting time as a measure of edoxaban anticoagulation reversal by PER977
Time Frame: 5 days
|
To evaluate the safety, tolerability and effect on whole blood clotting time of escalating intravenous doses of PER977 (25, 50, 100, 300 mg, and 600 mg) administered after 60 mg edoxaban as a "rescue" medication in healthy volunteers and repeated for a second day to investigate any effects of PER977 on the re-anticoagulation with edoxaban and second reversal with PER977.
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic profile of PER977
Time Frame: 5 days
|
To assess the maximal concentration, half-life and plasma and urinary clearance of PER977 and its metabolite following intravenous administration
|
5 days
|
Pharmacokinetic profile of edoxaban
Time Frame: 5 days
|
To evaluate the maximal concentration, half-life, and clearance of edoxaban and its metabolite when administered with PER977
|
5 days
|
Safety coagulation measures
Time Frame: 5 days
|
To evaluate changes in point of care prothrombin time, d-dimer, prothrombin factors 1 and 2, tissue factor pathway inhibitor, and possibly other biomarkers following escalating intravenous doses of PER977 administered after edoxaban in healthy volunteers
|
5 days
|
Safety and tolerability
Time Frame: 5 days
|
To determine if adverse events occurred in healthy volunteers who received PER977 after edoxaban
|
5 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analytical measurement range (AMR), reproducibility, and precision of WBCT measurements
Time Frame: 5 days
|
To determine to normal range, variability, and reproducibility of WBCT in blood collected from healthy volunteers
|
5 days
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PER977-02-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anticoagulation Reversal
-
Brigham and Women's HospitalCSL BehringRecruitingAnticoagulation | Anticoagulation ReversalUnited States
-
Perosphere Pharmaceuticals Inc, a wholly owned...CompletedAnticoagulant Reversal | Reversal of Edoxaban Induced AnticoagulationUnited States
-
HealthPartners InstituteCompletedHemorrhage | Acute Bleeding on Long-Term Anticoagulation Therapy | Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time) | Urgent Reversal of Vitamin K Antagonist (VKA) AnticoagulationUnited States
-
Vascular Solutions LLCWestat; United States Army Medical Materiel Development ActivityNot yet recruitingAnticoagulant ReversalUnited States
-
Cohera Medical, Inc.Completed
-
Charitable Union for the Research and Education...Active, not recruitingVasectomy ReversalUnited States
-
Cukurova UniversityCompletedIncomplete Reversal of Neuromuscular BlockTurkey
-
OctapharmaCompletedReversal of Anticoagulant TreatmentUnited States
-
Novocol Pharmaceutical of Canada, Inc.CompletedAnesthesia, Local | Dental Anesthesia | Anesthesia, ReversalUnited States
-
Stony Brook UniversityMerck Sharp & Dohme LLCCompletedIncomplete Reversal of Neuromuscular BlockUnited States
Clinical Trials on Edoxaban
-
Portola PharmaceuticalsCompleted
-
Daiichi Sankyo, Inc.The TIMI Study GroupCompletedStroke | Embolism | Atrial FibrillationUnited States, Australia, France, Italy, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Romania, Russian Federation, Serbia, South Africa, Turkey, Korea, Republic of and more
-
Daiichi Sankyo, Inc.CompletedDeep Vein Thrombosis | Venous ThromboembolismSpain, United States, United Kingdom, India, France, Canada, Italy, Lebanon, Turkey
-
Asan Medical CenterSamsung Medical Center; Pusan National University Hospital; Chonnam National... and other collaboratorsRecruitingAtrial Fibrillation | Acute Ischemic Stroke | Anticoagulant | Coronary Artery Atherosclerosis | Intracranial Atherosclerosis | Extracranial Atherosclerosis | Antiplatelet | Peripheral Artery StenosisKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
Montreal Heart InstituteServierActive, not recruitingValvular Heart Disease | Atrial Fibrillation and FlutterCanada
-
University of AlbertaCompletedIschemic Stroke | Atrial Fibrillation | Hemorrhagic Transformation StrokeCanada
-
Takeshi MorimotoCompletedNeoplasms | Venous Thrombosis | AnticoagulantJapan
-
Daiichi Sankyo, Inc.Completed
-
Institut universitaire de cardiologie et de pneumologie...WithdrawnBariatric Surgery Candidate